192 related articles for article (PubMed ID: 30830647)
21. Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
Beck M; Michel B; Rybarczyk-Vigouret MC; Levêque D; Sordet C; Sibilia J; Velten M;
BioDrugs; 2016 Dec; 30(6):585-592. PubMed ID: 27848166
[TBL] [Abstract][Full Text] [Related]
22. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
Chapman SR; Fitzpatrick RW; Aladul MI
BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy.
Giavatto C; Mourani J; Fitzpatrick C; Hardin B; Skrtic A; Evans A; Sredzinski E; Trieu S; Setter AI; Kobiska L; Lopez-Medina AI
J Manag Care Spec Pharm; 2024 Feb; 30(2):175-182. PubMed ID: 38308629
[TBL] [Abstract][Full Text] [Related]
24. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
25. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
[TBL] [Abstract][Full Text] [Related]
26. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):237-250. PubMed ID: 38175140
[TBL] [Abstract][Full Text] [Related]
27. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
28. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.
Grabowski D; Henderson B; Lam D; Keystone EC; Thorne C; Jamal S; Pope J; Haraoui B; Lin D; Revers L
Clin Rheumatol; 2015 Aug; 34(8):1427-33. PubMed ID: 25586522
[TBL] [Abstract][Full Text] [Related]
29. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Gasteiger C; Lobo M; Dalbeth N; Petrie KJ
Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866
[TBL] [Abstract][Full Text] [Related]
30. Pharmacists' viewpoint towards their professional role in healthcare system: a survey of hospital settings of Pakistan.
Khan N; McGarry K; Naqvi AA; Iqbal MS; Haider Z
BMC Health Serv Res; 2020 Jul; 20(1):610. PubMed ID: 32615966
[TBL] [Abstract][Full Text] [Related]
31. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
32. A survey of pharmacists' knowledge and views of biosimilars in Quebec and France.
Adé A; Bourdon O; Bussières JF
Ann Pharm Fr; 2017 Jul; 75(4):267-275. PubMed ID: 28237527
[TBL] [Abstract][Full Text] [Related]
33. Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars.
Aladul MI; Fitzpatrick RW; Chapman SR
Int J Pharm Pract; 2019 Apr; 27(2):214-217. PubMed ID: 30160324
[TBL] [Abstract][Full Text] [Related]
34. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
[TBL] [Abstract][Full Text] [Related]
35. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
36. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
37. Medical specialists' attitudes to prescribing biosimilars.
Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
[TBL] [Abstract][Full Text] [Related]
38. Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.
Azevedo A; Bettencourt A; Selores M; Torres T
Acta Med Port; 2018 Sep; 31(9):496-500. PubMed ID: 30332374
[TBL] [Abstract][Full Text] [Related]
39. Physicians' perceptions of the uptake of biosimilars: a systematic review.
Sarnola K; Merikoski M; Jyrkkä J; Hämeen-Anttila K
BMJ Open; 2020 May; 10(5):e034183. PubMed ID: 32371511
[TBL] [Abstract][Full Text] [Related]
40. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
